Inactive Instrument

Orchard Therapeutics plc

ORTX

US68570P2002

ORCHARD THERAPEUTICS PLC : Other Events, Financial Statements and Exhibits (form 8-K)

January 19, 2021 at 07:05 am

Item 8.01 Other Events.

On January 19, 2021, Orchard Therapeutics plc issued a press release announcing its entry into agreements with two regional specialty pharmaceutical companies. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
Number                                     Description
99.1        Press release dated January   19, 2021
104       Cover page interactive data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

Latest news about Orchard Therapeutics plc

Orchard Therapeutics Receives FDA Approval of Lenmeldy? (atidarsagene autotemcel)	03-18	CI
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome	02-05	CI
Japanese Shares Skid as Inflation Slows Faster-than-Expected in January	01-26	MT
Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics	01-25	MT
Orchard Therapeutics plc Announces Board Changes	01-24	CI
Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin	01-24	MT
Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index	01-24	CI
Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.	01-23	CI
Orchard Therapeutics’ Gene Therapy Gets Swiss Regulatory Approval	12-11	MT
Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy	12-11	CI
Orchard Therapeutics Gets FDA Fast Track Designation for Enzyme Deficiency Treatment	11-30	MT
Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH	11-30	CI
Earnings Flash (ORTX) ORCHARD THERAPEUTICS (EUROPE) LIMITED Posts Q3 Revenue $6.3M	11-13	MT
Orchard Therapeutics plc Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-13	CI
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023	23-10-26	CI
Japanese Shares Close Lower on Losses by Electronics, Energy Stocks; Kyowa Kirin Adds 1%	23-10-06	MT
Kyowa Kirin to Wholly Acquire Outstanding Shares of Orchard Therapeutics	23-10-06	MT
ADRs End Higher; Orchard Therapeutics PLC Climbs 96%	23-10-05	DJ
US Equity Markets Close Down Thursday as Jobless Claims Rise Less Than Forecast	23-10-05	MT
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-05	MT
Top Midday Gainers	23-10-05	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	23-10-05	MT
Sector Update: Health Care	23-10-05	MT
Cantor Fitzgerald Downgrades Orchard Therapeutics to Neutral From Overweight, Raises Price Target to $16 From $15	23-10-05	MT
FTSE 100 Closed Up 0.5% Despite Oil Price Drag	23-10-05	DJ

Chart Orchard Therapeutics plc

Duration

Period

More charts

Company Profile

Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient's autologous HSCs into a gene-modified cellular drug product to treat the patient's disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals